Half-year report · Q2
4005.TEDINET S100UN1U
Period2024-04-01 → 2024-09-30
Filed2024-11-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.24T | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.45T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.19T | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥121.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | −¥133.7bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥30.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥462.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥103.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥311.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥76.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥465.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥107.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.72T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥3.93T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.38T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.63T | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.77T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.09T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.55T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.49T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥909.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥965.8bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.22T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥273.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥277.7bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥305.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥63.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥51.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥115.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥74.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥112.2bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥79.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥75.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥49.2bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥140.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-3.99 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-190.69 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-46.69 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| Equity ratio | 24.5% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.9% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥78.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥41.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥37.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥15.7bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥50.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥50.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥10.0bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥147.5bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥138.8bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.7bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.7bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥405.9bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥403.0bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥36.6bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥239.5bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥238.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.6bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥224.6bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥224.3bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥235m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥37.5bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥195.2bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥195.2bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥470m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.21T |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.20T |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥13.0bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥23.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥76.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥34.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥41.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥56.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥56.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥7.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥159.8bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥149.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥393.1bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥390.3bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥44.4bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥243.1bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥241.2bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7.6bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥203.9bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥203.7bn |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥220m |
| jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥17.8bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥166.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥166.9bn |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E00752-000Medical Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥65.5bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.17T |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.15T |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥14.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥93.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 919
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | 1589000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -28612000000 | JPY |
| Increase decrease in trade payables ope cf IFRS | Prior1YTDDuration | -28167000000 | JPY |
| Increase decrease in trade payables ope cf IFRS | CurrentYTDDuration | 10406000000 | JPY |
| Increase decrease in unearned revenue ope cf IFRS | Prior1YTDDuration | -8194000000 | JPY |
| Increase decrease in unearned revenue ope cf IFRS | CurrentYTDDuration | -4661000000 | JPY |
| Increase decrease in provisions ope cf IFRS | Prior1YTDDuration | -40987000000 | JPY |
| Increase decrease in provisions ope cf IFRS | CurrentYTDDuration | -1207000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -78154000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | 51653000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | -64486000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 77916000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 12708000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 11869000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -13940000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -14513000000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YTDDuration | -23703000000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYTDDuration | 2157000000 | JPY |
| Business structure improvement expenses paid ope cf IFRS | Prior1YTDDuration | -25891000000 | JPY |
| Business structure improvement expenses paid ope cf IFRS | CurrentYTDDuration | -13883000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | -115312000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 63546000000 | JPY |
| Decease increase of marketable securities inv cf IFRS | Prior1YTDDuration | -6669000000 | JPY |
| Decease increase of marketable securities inv cf IFRS | CurrentYTDDuration | -5668000000 | JPY |
| Purchase of non current assets inv cf IFRS | Prior1YTDDuration | -78633000000 | JPY |
| Purchase of non current assets inv cf IFRS | CurrentYTDDuration | -75298000000 | JPY |
| Proceeds from sales of non current assets inv cf IFRS | Prior1YTDDuration | 667000000 | JPY |
| Proceeds from sales of non current assets inv cf IFRS | CurrentYTDDuration | 13705000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | Prior1YTDDuration | 11074000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | CurrentYTDDuration | 4079000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -2991000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | -2062000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | Prior1YTDDuration | 26911000000 | JPY |
| Proceeds from sale of investments inv cf IFRS | CurrentYTDDuration | 143509000000 | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YTDDuration | 297000000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYTDDuration | 53000000 | JPY |
| Payments for loans receivable inv cf IFRS | Prior1YTDDuration | -25918000000 | JPY |
| Payments for loans receivable inv cf IFRS | CurrentYTDDuration | -30000000 | JPY |
| Other inv cf IFRS | Prior1YTDDuration | -4523000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | -3866000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -79785000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | 74422000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | 92943000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | -65479000000 | JPY |
| Net increase decrease in commercial paper fin cf IFRS | Prior1YTDDuration | 26000000000 | JPY |
| Net increase decrease in commercial paper fin cf IFRS | CurrentYTDDuration | -17000000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YTDDuration | 30032000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | 72000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -14537000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -54633000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |